Good Morning Investors!!! The defining problem for Merck is still a calendar date. U.S. biosimilar competition for Keytruda could begin in December 2028, with two additional patents running into 2029, and the drug produced roughly half of Merck’s 2025 sales. Friday’s bladder cancer approval expands the franchise into an earlier, potentially curative setting, but it does not extend the original Keytruda patents. The real test is whether the new indication grows volume while QLEX captures enough of that volume to soften the decline later this decade.
Extending the Keytruda Timeline
Verdict: Merck and its partners just expanded Keytruda plus Padcev into all adults with muscle invasive bladder cancer who are candidates for bladder removal surgery, regardless of cisplatin eligibility. The clinical result is strong, but the patent defense angle is smaller than it first appears because the pivotal trial used intravenous Keytruda and the Padcev portion of the regimen still requires an intravenous infusion.
What happened
fThe approval also includes Keytruda On Friday, the FDA expanded approval of Merck’s Keytruda or Keytruda QLEX plus the Pfizer and Astellas drug Padcev before and after bladder removal surgery for adults with muscle invasive bladder cancer. The regimen had already been approved for patients who could not receive cisplatin. Friday’s decision extends it to all patients who are candidates for surgery, making it the first approved platinum free regimen for that full population.
The approval also permits the use of Keytruda QLEX, the subcutaneous version of pembrolizumab that was broadly approved in September 2025. QLEX itself can be injected in one to two minutes instead of a thirty minute Keytruda infusion. But the 35% reduction in the risk of death came from a trial using intravenous Keytruda, not QLEX, and Padcev still requires a thirty minute intravenous infusion on days one and eight of each cycle. The full treatment is therefore not a two minute visit.
Why it matters
The basic math for Merck still revolves around the patent cliff. Keytruda and QLEX generated $31.7 billion in 2025, about 49% of total sales, and Merck says U.S. biosimilar competition could begin in December 2028, with other patents running into 2029. QLEX is one part of the defense, not the whole answer. Management is targeting 30% to 40% QLEX adoption by 2028, and QLEX sales were $128 million in the first quarter against $8.0 billion for the combined Keytruda franchise. This approval adds eligible patients, but because Padcev remains intravenous, it is not the cleanest setting for proving the convenience advantage.
What changed in the thesis
Earlier stage approvals are still a volume game, but this one adds a more complicated commercial test. Merck first needs the regimen to become a standard of care, then needs a meaningful share of patients to use QLEX instead of intravenous Keytruda before biosimilars arrive. Because Padcev remains an infusion, clinic economics may help QLEX adoption, but the convenience advantage is smaller here than it is for patients receiving Keytruda alone.
What the market may be missing
AstraZeneca faces a tougher competitive setup, but calling Imfinzi obsolete goes too far. Its approved perioperative regimen still uses gemcitabine and cisplatin, while Merck and its partners now have the first approved platinum free option for all patients who are candidates for surgery. There is no head to head trial, and AstraZeneca has already reported positive Phase 3 results for a separate platinum free Imfinzi plus enfortumab vedotin regimen in patients who could not take or declined cisplatin. The pressure is real, but the competitive story is not settled.
Valuation and expectations
Merck currently trades near 14 times forward earnings. That assumes the coming revenue destruction will be manageable. If commercial insurers push back on this new combination therapy, which can cost more than $500,000 annually per patient, peak revenue models could come down. The key variable is adoption speed for the quick injection format.
Bottom line
The clinical data is strong, and removing chemotherapy is a clear win for patients. But for shareholders, the real victory is locking in a new standard of care using a proprietary format that competitors cannot easily copy when the original patents expire.
- S&P 500 futures are down roughly 0.3% early Monday, while Nasdaq 100 futures are off about 1.0%, as renewed U.S. Iran attacks lift oil prices and hit chip stocks.
- Merck shares are up roughly 0.4% in early pre market action near $124, a modest move after the approval was announced during Friday’s session.
- Healthcare is showing some defensive relative strength, with the XLV sector ETF up roughly 0.5% pre market even as broader growth stocks sell off.
Why it matters this morning
Today’s tape is more about macro risk than this FDA decision. Merck is outperforming modestly, but the approval was public before Friday’s close, so Monday’s pre market move is not a clean first reaction. For a long term investor, the useful question is whether the new regimen expands the addressable market and builds QLEX use, not whether defensive rotation lifts the shares for one morning.
Pfizer (PFE)
The company is a partner on Padcev and shares the direct upside of this new standard of care. Pfizer carries a $137 billion market capitalization and trades near 18.5 times earnings.
Astellas Pharma (TSE 4503)
The co developer of Padcev is already recognizing significant sales growth from the drug. The company features a roughly $24 billion market capitalization and a price to earnings ratio near 13.
AstraZeneca (AZN)
The competitor commands a massive $266.5 billion market capitalization and trades at a premium 26 times earnings multiple. That premium could be tested now that its Imfinzi regimen looks less attractive because it requires older cisplatin chemotherapy.
Group takeaway
The approval establishes a new competitive standard. Companies offering platinum free treatments can capture market share, while competitors relying on older chemotherapy protocols face immediate estimate risk.
- Merck will hold an earnings call in early August, which should provide updated guidance on Keytruda QLEX adoption rates.
- Prescription volume data over the next two quarters will show how quickly oncologists abandon traditional chemotherapy for the new combination.
- AstraZeneca is likely to face questions on its next earnings report regarding Imfinzi market share erosion in bladder cancer.
- Medicare price negotiations under the Inflation Reduction Act could compress margins on these expensive combination therapies before the original patents expire.
Bottom line
The timeline for Keytruda revenue is the single most important variable for Merck investors. Tracking how quickly clinics adopt the new two minute injection format will show whether management can successfully push the patent cliff out into the next decade.
Disclosure
Disclosure: At the time of publication, the author has no long or short position in any securities mentioned and does not plan to initiate a position within 72 hours of publication. The author was not compensated by any company mentioned in this article.
Important Disclaimer
InvestorsGrow and the Morning Note are published for informational and educational purposes only. Nothing in this email or on InvestorsGrow.com should be considered personalized investment, financial, legal, tax, or accounting advice, or a recommendation to buy, sell, or hold any security. The content is general in nature and does not take into account your investment objectives, financial situation, risk tolerance, or individual needs. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. Opinions are as of the publication date and may change without notice. Data and information are believed to be reliable but are not guaranteed. The author, InvestorsGrow, affiliates, and/or contributors may hold, buy, or sell securities discussed. Article-specific positions, compensation, or conflicts are disclosed where applicable. You are solely responsible for your own investment decisions and should conduct your own research and consult a qualified professional before making financial decisions.
Full disclosures and terms are available at InvestorsGrow Disclosures & Terms .
|
About the Author Founder & Editor, InvestorsGrow.com Jimmy Copell is the founder and editor of InvestorsGrow.com and creator of the Learn to Invest – Investors Grow YouTube channel. A former Wall Street equity research analyst with a master’s degree in Security Analysis from Creighton University, Jimmy focuses on plain-English market commentary, company fundamentals, valuation, earnings, and risk for long-term, self-directed investors. |
